What are the drug interactions and risks when combining lamotrigine (Lamictal), quetiapine (Seroquel), and the dextromethorphan‑bupropion combination (Auvelity)?

Lamictal, Seroquel, and Auvelity Combination: Key Interactions and Management

This three-drug combination carries significant interaction risks that require careful monitoring: lamotrigine substantially reduces quetiapine levels (particularly with immediate-release formulations), while Auvelity poses risks for serotonin syndrome, seizures, hypertension, and neuropsychiatric effects when combined with other psychotropics.

Critical Drug-Drug Interactions

Lamotrigine-Quetiapine Interaction

Lamotrigine significantly reduces quetiapine serum concentrations through UDP-glucuronosyltransferase enzyme induction, with the effect being both dose-dependent and formulation-specific 1, 2.

The interaction severity depends on two factors:

• Lamotrigine dose: High-dose lamotrigine (>200 mg/day) reduces quetiapine immediate-release (IR) concentrations by 46% compared to controls, while low-dose lamotrigine (≤200 mg/day) shows no significant interaction 2
• Quetiapine formulation: The interaction is clinically significant only with quetiapine IR tablets. Quetiapine extended-release (XR) formulations show no significant concentration changes regardless of lamotrigine dose 1, 2

Clinical impact: In patients receiving quetiapine IR with lamotrigine, 50% had plasma concentrations below the therapeutic reference range compared to only 30% on monotherapy 1. This represents a 31% reduction in absolute plasma concentrations and 23% reduction in dose-adjusted concentrations 1.

Auvelity-Related Interactions

Auvelity (dextromethorphan/bupropion) carries multiple FDA warnings regarding drug interactions 3:

Serotonin syndrome risk: The FDA label explicitly warns about serotonin syndrome when Auvelity is combined with SSRIs or tricyclic antidepressants 3. While quetiapine has some serotonergic activity, this risk is lower than with traditional serotonergic agents but still warrants monitoring.

Seizure risk: Auvelity can cause seizures, and this risk increases with abrupt discontinuation of antiepileptic drugs like lamotrigine 3. The bupropion component lowers seizure threshold.

Hypertension and blood pressure elevation: Auvelity increases blood pressure, with heightened risk when combined with drugs that increase dopaminergic or noradrenergic activity 3. Quetiapine's alpha-adrenergic blocking properties may partially counteract this, but monitoring remains essential.

Neuropsychiatric effects: Bupropion can cause delusions, hallucinations, psychosis, concentration disturbances, paranoia, and confusion 3. Combined with quetiapine (an antipsychotic), this creates a pharmacodynamic contradiction requiring careful assessment.

Cardiac Considerations

Both quetiapine and lamotrigine have cardiac implications that require attention 4:

• Quetiapine is classified as having propensity for QT prolongation (Class B in the European Heart Journal classification system) 4
• Lamotrigine and other anticonvulsants used as mood stabilizers have generally not been associated with severe arrhythmia, though lithium (another mood stabilizer) requires caution 4
• The combination does not appear to create additive cardiac risk beyond quetiapine's baseline QT effects

Management Algorithm

1. Optimize Quetiapine Formulation

• Switch to quetiapine XR if currently using IR formulation to eliminate the lamotrigine interaction effect 1, 2
• If quetiapine IR must be continued, therapeutic drug monitoring (TDM) is strongly recommended 2

2. Lamotrigine Dose Considerations

• If lamotrigine dose is ≤200 mg/day and quetiapine IR is used, the interaction is minimal 2
• If lamotrigine dose is >200 mg/day, either switch quetiapine to XR or increase quetiapine dose with TDM guidance 2

3. Monitor for Auvelity-Specific Risks

Serotonin syndrome surveillance (especially during initiation and dose changes):

• Agitation, confusion, rapid heart rate
• Dilated pupils, loss of muscle coordination
• Muscle rigidity, heavy sweating
• Diarrhea, headache, shivering
• Instruct patient to seek emergency care if these occur 3

Seizure precautions:

• Ensure lamotrigine is maintained at stable doses; avoid abrupt changes 3
• Counsel patient to avoid alcohol and maintain consistent sleep patterns
• Discontinue Auvelity permanently if seizure occurs 3

Blood pressure monitoring:

• Baseline blood pressure before starting Auvelity
• Recheck at 1-2 weeks, then monthly for first 3 months
• More frequent monitoring if patient has hypertension history

Neuropsychiatric monitoring:

• Assess for new-onset psychotic symptoms, confusion, or mood destabilization
• This is particularly important given the pharmacodynamic opposition between bupropion (activating) and quetiapine (sedating/antipsychotic)

4. Baseline and Follow-up Assessments

• ECG if patient has cardiac risk factors or is on quetiapine doses >300 mg/day 4
• Liver function tests (all three medications undergo hepatic metabolism)
• Therapeutic drug monitoring of quetiapine if using IR formulation with lamotrigine >200 mg/day 2

5. Dosing Timing

• Maintain at least 8-hour interval between Auvelity doses (maximum 2 tablets daily) 3
• No specific timing requirements for lamotrigine or quetiapine relative to Auvelity

Common Pitfalls to Avoid

• Assuming all quetiapine formulations interact equally with lamotrigine: The XR formulation avoids this interaction 1, 2
• Overlooking subtherapeutic quetiapine levels: 50% of patients on IR quetiapine with lamotrigine have subtherapeutic levels 1
• Missing early serotonin syndrome signs: This can progress rapidly and requires immediate intervention 3
• Abruptly adjusting lamotrigine while on Auvelity: This increases seizure risk 3
• Failing to counsel about alcohol: Alcohol increases seizure risk with Auvelity and should be minimized or avoided 3

Patient-Specific Factors Requiring Extra Caution

• History of seizures (relative contraindication for Auvelity)
• Eating disorders (increased seizure risk with bupropion)
• Bipolar disorder (monitor for mania activation with Auvelity) 3
• Angle-closure glaucoma risk (Auvelity can cause pupillary dilation) 3
• Falls risk or motor impairment (Auvelity causes dizziness) 3
• Pregnancy (Auvelity has embryo-fetal toxicity warnings) 3